Karen Van Baelen, MD, KU Leuven, Leuven, Belgium, discusses the significance of HER2 low status in lobular breast cancer (LBC) and how this may impact patient treatment decisions. Dr Van Baelen highlights that although 50% of HER2 negative breast cancers are also HER2 low status, the development of antibody drug conjugates (ADCs) that appear to demonstrate favourable outcomes, offers a promising avenue to be explored through further clinical trials. This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.